ClinicalTrials.gg
Not yet recruitingNCT07626164Updated Jun 4, 2026

Three Photobiomodulation Wavelengths (635, 940, and 1064 nm) on Chronic Myogenic Temporomandibular Disorder

An interventional study of 635 nm red diode laser and 940 nm NIR diode laser (Biolase) in Temporomandibular Disorders, sponsored by Alexandria University. Not yet recruiting at 1 site in Egypt. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Temporomandibular Joint Disorders with a site in Egypt — 10 open to participants now, 14 under way, none of them phase 3. Temporomandibular Joint Disorders · Egypt.

Planned enrollment
12th of 49
45 · median 30
Started
2026
with 6 others
No phase
42 of 63
9 open now
Primary completion
2026-12
later than 10 of 13 live
Registered
59th of 63
by date
Lead sponsor
4 of 63
Alexandria University

Among the 63 studies in Temporomandibular Joint Disorders with a site in Egypt, this one is the 12th largest by planned enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2026, is one of 42 with no phase, reaches primary completion later than 10 of the 13 other live ones, and was the 59th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

10 of the 63 studies in Temporomandibular Joint Disorders with a site in Egypt are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 20 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Temporomandibular Joint Disorders with a site in Egypt, or all of them as a file.
02

Study summary

Temporomandibular disorders (TMDs) are among the most common musculoskeletal conditions associated with chronic orofacial pain and functional disability. Chronic Myogenic TMD (MTMD) is the most prevalent subtype and is characterized by persistent masticatory muscle pain driven by peripheral and central sensitization mechanisms. Photobiomodulation (PBM) represents a conservative, non-invasive therapeutic modality within the medical management of TMD; however, the wavelength-dependent clinical and muscular effects remain inadequately defined. Aim: To compare the efficacy of three PBM wavelengths (635, 940, 1,064 nm) on pain intensity, mandibular function, surface electromyographic activity (sEMG), and pressure pain threshold (PPT) in patients with chronic myogenic TMD.

03

Conditions studied

  • Temporomandibular Disorders
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suffering from chronic myogenic TMD based on diagnostic criteria for diagnosis of temporomandibular joint disorders (DC/TMD) criteria. (pain increases with jaw opening, chewing, or clenching).
  • Patients suffering of unilateral or bilateral chronic pain (> 3 months' duration) related to masseter and temporalis muscles(30).
  • Patients suffering of moderate-to-severe pain intensity ≥ 4 on a 0-10 VAS
  • Patients that have not responded to conservative modes of treatment during the study and up to 3 months after last intervention. (medications, physiotherapy, splints).

Exclusion criteria

Exclusion Criteria:

  • Patients suffering from chronic systematic conditions that alter pain sensitivity; neurological diseases, pain of dental origin, pregnancy or lactation, high blood pressure, diabetes milletus, rheumatic inflammatory disease, fibromyalgia, obstructive sleep apnea, and restrictions for the use of laser (pacemakers).
  • Participants on medications that affect pain sensitivity and perception during the last 2 weeks: anticoagulants, analgesics, or antidepressants.
  • History of surgery, arthropathy (joint disorders), facial trauma, malignant tumors or fractures in the orofacial region, neuropsychological or hormonal problems
  • Treatments: orthodontics, splints, major occlusal rehabilitation, prosthodontic therapy, previous PBM, TENS therapy, or botox for TMD in the last 6 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    PBM therapy I

    Other: 635 nm red diode laser

  • Experimental
    PBM therapy II

    Other: 940 nm NIR diode laser (Biolase)

  • Experimental
    PBM therapy III

    Other: 1064 nm Nd:YAG laser (Fotona)

Interventions

  • Other635 nm red diode laser

    Participants will receive PBM therapy using a 635 nm red diode laser (Lasotronix), standardized at a fluence of 8 J/cm² for energy density and Irradiance of 0.50 W/cm² power density in continuous wave using PBM applicator (8mm tip) for 16 seconds, near-contact working distance.

  • Other940 nm NIR diode laser (Biolase)

    Participants will receive PBM therapy using a 940 nm NIR diode laser (Biolase), standardized at a fluence of 8 J/cm² and Irradiance of 0.63 W/cm² power density in continuous wave using deep tissue handpiece (10mm tip) for 12.8 seconds.

  • Other1064 nm Nd:YAG laser (Fotona)

    Participants will receive PBM therapy using a 1064 nm Nd:YAG laser (Fotona), standardized at a fluence of 8 J/cm² energy density and Irradiance 0.53 W/cm² power density, using a genova handpiece (11mm tip) stamping technique for 15.2 sec.

06

What researchers measure

Primary outcomes

  1. Change in subjective Pain Intensity

    It will be assessed using both visual analog scale (VAS) at baseline, 7,14,21 days, and 4, 12 weeks

    Time frame: up to 12 weeks

Secondary outcomes

  1. Change in maximum mouth opening

    Functional maximum mouth opening (MMO) unassisted and in the pain-free opening range (PFO) by digital caliper at baseline, 7,14,21 days, and 4, 12 weeks.

    Time frame: up to 12 weeks

  2. Change in muscles activity

    Surface electromyography (sEMG) activity during rest and maximum voluntary clenching (MVC) activity using surface electrodes

    Time frame: up to 12 weeks

  3. Change in Number of tender points

    by palpation pressure of muscles

    Time frame: up to 12 weeks

  4. Change in pressure pain threshold

    Pressure pain threshold (PPT) over the most tender point of the masseter and temporalis muscles by a pressure algometer (PA) to measure the degree of tenderness over the most tender points at the muscles

    Time frame: up to 12 weeks

07

Study locations

1 site
  • Outpatient Clinic of Oral medicine Department, Faculty of Dentistry, Alexandria University, Egypt
    Alexandria, Egypt
    • Faculty of Dentistry · Contact(203) 4868308
    • Ahmed Shafik, BDS · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 6 months is below that.

Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 4, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07626164
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jun 4, 2026

Study contacts

Ahmed Shafik, BDS
Contact
safwat4dental@gmail.com
01275607044 ext. 002

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion